On Friday, BofA Securities adjusted its outlook on Doximity Inc (NYSE:DOCS), a healthcare technology company, by increasing its price target from $45.00 to $54.00. Despite the higher price target, the firm maintained a Neutral rating on the company's stock.
Doximity has recently reported a robust financial performance, outpacing Wall Street's expectations in terms of revenue and EBITDA. This strong showing has been attributed to the company's operational leverage and the low-cost nature of its business model, which has become increasingly evident as revenue growth picks up pace.
The company had previously projected long-term adjusted EBITDA margins to exceed 45% during its investor day in the summer. However, with revenue growth now accelerating to mid-teens or higher, the firm sees potential for these margins to remain sustainably high, between 50% and 55%, particularly if Doximity continues to be the preferred platform for top pharmaceutical companies.
Doximity's strategic management of operating expenses has been commendable, especially in the development of new products such as Point of Care, Peer to Peer, and the client portal. This has positioned the platform as a favorite among the top 20 pharmaceutical firms, as reflected in the company's robust net revenue retention within this group.
The analyst noted that while the company's growth is impressive, the current share valuation is seen as fair, even at these higher levels. The price target increase to $54 reflects a multiple of 32 times the projected CY25 EBITDA, up from the previous multiple of 29 times. This adjustment has been made to acknowledge Doximity's recent improvements in execution.
In other recent news, Doximity Inc has been the subject of several revisions by analyst firms. KeyBanc Capital Markets has upgraded Doximity's stock from Sector Weight to Overweight and set a new price target of $70.00, following the company's robust second-quarter financial report. Barclays (LON:BARC) also upgraded Doximity's stock from Equalweight to Overweight, raising the price target to $52, reflecting an optimistic outlook on the company's growth prospects.
BofA Securities raised its price target for Doximity from $32 to $45, maintaining a Neutral rating, following a survey reflecting an uptick in advertising spend. Similarly, Jefferies maintained a Buy rating on Doximity and increased the price target to $43, highlighting the success of new product introductions and the Client Portal.
Canaccord Genuity also maintained a Buy rating on Doximity, expressing confidence in the company's new Portal offering and its potential to significantly impact long-term growth. The firm raised its price target to $40 from $37.
In other company news, Doximity recently re-elected two directors and ratified Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending March 31, 2025. These are the recent developments that have emerged from the company's recent financial performance and strategic moves.
InvestingPro Insights
Doximity's recent financial performance and BofA Securities' increased price target are further supported by key metrics from InvestingPro. The company's impressive gross profit margin of 89.65% for the last twelve months as of Q1 2023 aligns with BofA's observation of Doximity's operational leverage and low-cost business model. This is reinforced by an InvestingPro Tip highlighting Doximity's "impressive gross profit margins."
The company's strong market position is reflected in its market capitalization of $8.06 billion and a significant price total return of 106.07% over the past year. This performance supports the analyst's view of Doximity's growing popularity among pharmaceutical companies and its potential for sustained high margins.
However, investors should note that Doximity is trading at a high P/E ratio of 50.93, which corresponds with BofA's assessment that the current share valuation is fair even at higher levels. This is further emphasized by an InvestingPro Tip indicating that the stock is "trading at a high earnings multiple."
For readers interested in a more comprehensive analysis, InvestingPro offers 13 additional tips for Doximity, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.